
1. bioorg med chem lett. 2011 oct 15;21(20):6031-5. doi: 10.1016/j.bmcl.2011.08.083.
epub 2011 aug 24.

effect lipophilicity modulation inhibition human rhinovirus capsid
binders.

morley a(1), tomkinson n, cook a, macdonald c, weaver r, king s, jenkinson l,
unitt j, mccrae c, phillips t.

author information: 
(1)department chemistry, astrazeneca r&d charnwood, bakewell road,
loughborough le11 5rh, uk. andy.morley@astrazeneca.com

to try generate broad spectrum human rhinovirus vp1 inhibitors more
attractive physicochemical, dmpk safety profiles, explored current sar
of known vp1 compounds. lead identification specific structural
regions reduction polarity achieved, guiding chemistry to
analogues significantly superior profiles previously reported inhibitors.

copyright Â© 2011 elsevier ltd. rights reserved.

doi: 10.1016/j.bmcl.2011.08.083 
pmid: 21907579  [indexed medline]

